10-Q: Cryo-Cell International Q2 2026 Results Show Revenue Dip, Legal Battles Continue

Cryo-Cell International reports a 2% revenue decrease for the quarter ended May 31, 2026, amidst ongoing arbitration with Duke University and NYSE listing concerns.

Summary

• Revenue for the six months ended May 31, 2026, was $15.46 million, a decrease from $15.90 million in the prior year period.
• Processing and storage fees, the primary revenue driver, saw a slight decrease due to fewer new domestic cord blood specimens processed.
• Cost of sales decreased by 13% for the six-month period, contributing to a slight improvement in operating profit.
• Selling, general, and administrative expenses increased by 8% for the six-month period.
• The company is involved in ongoing arbitration with Duke University, with a final hearing scheduled for late July 2026.
• Cryo-Cell received a notice of termination from Duke University regarding their License Agreement.
• The company is also facing challenges with NYSE American continued listing requirements, with a plan of compliance submitted and an extension granted until September 9, 2027.
• Cash and cash equivalents increased to $507,302 as of May 31, 2026, from $319,031 at November 30, 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to declining revenues, significant ongoing legal disputes, and concerns regarding stock exchange listing compliance, overshadowing operational improvements.

Positives

• Cash and cash equivalents increased to $507,302 as of May 31, 2026, up from $319,031 at November 30, 2025.
• Cost of sales decreased by 13% for the six months ended May 31, 2026, compared to the same period in 2025.
• Net cash provided by operating activities increased to $2,497,738 for the six months ended May 31, 2026, from $1,661,077 in the prior year.
• The company has a plan of compliance accepted by NYSE American, with an extension until September 9, 2027, to regain compliance with listing standards.

Negatives

• Total revenue for the six months ended May 31, 2026, was $15.46 million, a decrease from $15.90 million in the prior year.
• Processing and storage fees decreased due to a 14% drop in new domestic cord blood specimens processed in the first six months of fiscal 2026.
• Public cord blood banking revenue significantly decreased to $47,895 from $124,767 for the six-month period.
• Selling, general, and administrative expenses increased by 8% for the six-month period.
• The company is involved in a significant legal dispute with Duke University, including an arbitration demand and a notice of termination of their license agreement.
• Cryo-Cell is not in compliance with NYSE American continued listing standards and faces potential delisting if compliance is not achieved by September 9, 2027.

Risks

• The ongoing arbitration with Duke University and the potential termination of the license agreement could materially and negatively impact the company's business, financial position, and results of operations.
• Failure to regain compliance with NYSE American continued listing requirements by September 9, 2027, could lead to delisting, depressing stock price and limiting liquidity and the ability to raise capital.
• The company may need to raise additional capital to regain compliance with NYSE American listing rules, with no assurance of success.
• The company's ability to commercialize rights licensed under the Duke License Agreement, treat patients, or spin off Celle Corp. is unlikely until the dispute is resolved.
• The opening of the Cryo-Cell Institute for Cellular Therapies is on pause due to the Duke dispute.
• A decrease or slowdown in the number of people seeking to store umbilical cord blood stem cells or paying annual storage fees could adversely impact revenue.
• Technological or medical breakthroughs could render the business of stem cell preservation obsolete.
• Material failure or malfunction in storage facilities, or natural disasters, could adversely affect stored specimens.

Future Outlook

The company anticipates that its cash and cash equivalents, marketable securities, and cash flows from operations, along with external capital sources, will be sufficient to fund its known cash needs for at least the next 12 months. However, future funding needs, particularly related to the Duke License Agreement dispute, are currently unpredictable. The company may require additional capital for startup expenses, clinical trials, biopharmaceutical manufacturing capabilities, and capital expenditures if the Duke dispute resolution necessitates it. There is no assurance that additional debt or equity financing will be obtainable on favorable terms.

Management Comments

• Management believes that the resolution of the Duke counterclaims should not have a material adverse effect on the Company's business, consolidated financial position or results of operations, but acknowledges the possibility of an unfavorable outcome.
• Management believes that its cash and cash equivalents, marketable securities and cash flows from operation, together with external sources of capital will be sufficient to fund its known cash needs for at least the next 12 months.
• Management is unable to predict funding needs for activities related to the Duke License Agreement until the dispute is resolved.
• Management has concluded that disclosure controls and procedures were fully effective as of the end of the period covered by the report.

Industry Context

StockSavvy.ai notes that Cryo-Cell International operates in the specialized field of cord blood and tissue banking, a sector influenced by advancements in regenerative medicine and cellular therapies. The company's financial performance is closely tied to its ability to attract new clients for its core storage services and manage its operational costs. The ongoing legal dispute with Duke University and the challenges with NYSE listing requirements represent significant headwinds that could impact its strategic growth initiatives and market position.

Comparison to Industry Standards

• The company's revenue for the six months ended May 31, 2026, of $15.46 million, is compared against its own historical performance, showing a slight decline.
• The decrease in new domestic cord blood specimens processed by 14% (for the six-month period) suggests a potential slowdown in market penetration or increased competition within the private cord blood banking sector.
• The company's focus on cGMP/cGTP compliance and AABB/FACT accreditation aligns with industry best practices for cellular therapy and storage facilities.
• The company's historical 100% viability rate of specimens upon thaw for therapeutic use is a key differentiator against industry benchmarks.

Legal Proceedings

• Arbitration Demand filed by Cryo-Cell against Duke University alleging fraudulent inducement and breach of contract, with damages sought exceeding $100 million.
• Duke University has filed counterclaims for breach of the License Agreement and indemnity.
• Duke University has issued a notice of termination of the License Agreement as of May 17, 2025.
• The company is not in compliance with NYSE American continued listing standards and has submitted a plan of compliance, with an extension until September 9, 2027.

Stakeholder Impact

• Shareholders: Potential for stock price decline due to NYSE listing concerns and legal disputes; dilution risk from potential future equity raises.
• Creditors: The company's credit agreement with Susser Bank includes covenants that must be maintained.
• Employees: Uncertainty surrounding future investments and strategic direction due to legal disputes may impact morale and job security.
• Customers: Continued provision of core cord blood and tissue storage services is expected, but expansion plans are on hold.

Next Steps

• Continue to monitor and manage operations to meet NYSE American continued listing requirements by September 9, 2027.
• Pursue resolution of the arbitration with Duke University, with a final hearing concluding in late July 2026.
• Manage cash flow and operations to ensure sufficiency for at least the next 12 months.
• Evaluate potential need for additional capital raises to address listing compliance or Duke dispute-related activities.

Key Dates

Recommendation

The company faces significant headwinds including declining revenues, a major legal dispute with Duke University, and potential delisting from the NYSE American. While operational costs have been managed, the uncertainties surrounding the legal outcome and listing compliance outweigh the current operational performance, warranting a cautious 'hold' stance until these critical issues are resolved.

Keywords

Cryo-Cell International, 10-Q Filing, Cord Blood Storage, Stem Cells, Duke University Arbitration, NYSE Listing, Financial Results, Quarterly Report